Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02448771 · ClinicalTrials.gov registry record · Phase 1
A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT02448771 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 36 participants.
The verdict
NCT02448771, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This research study is studying a drug called Palbociclib in combination with Bazedoxifene (a type of endocrine therapy, which prevents breast cancer cell growth by blocking estrogen stimulation) as a possible treatment for this diagnosis. The names of the study interventions involved in this study are: * Palbociclib * Bazedoxifene
Interventions
- DRUG Palbociclib
- DRUG Bazedoxifene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2015-07-09 |
| Est. Completion | 2021-03-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02448771
The ClinicalTrials.gov registry entry for NCT02448771 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Palbociclib is the first listed.
NCT02448771 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02448771 about?
NCT02448771 is a clinical study titled "A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer". This research study is studying a drug called Palbociclib in combination with Bazedoxifene (a type of endocrine therapy, which prevents breast cancer cell growth by blocking estrogen stimulation) as a possible treatment for this diagnosis. The names of the study interventions involved in this study...
What is the current status of trial NCT02448771?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2015-07-09. Estimated completion is 2021-03-03.
What interventions are being tested in trial NCT02448771?
The interventions under investigation include: Palbociclib (DRUG), Bazedoxifene (DRUG).
Who is sponsoring clinical trial NCT02448771?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.